Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-alpha). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, new-onset psoriasis in a patient on infliximab for rheumatoid arthritis.
Chan
Chung-Yin Stanley
CY
Browning
John C
JC
Larsen
Fiona
F
Hsu
Sylvia
S
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000276:immunology; D005260:Female; D006801:Humans; D000069285:Infliximab; D015603:Keratinocytes / Q000187:drug effects; D011565:Psoriasis / Q000139:chemically induced* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab